CTLA4 and non-small cell lung carcinoma: In the coming years, additional improvements in survival outcomes are expected due to the introduction of immunotherapy, which has been used in clinical practice to treat advanced NSCLC since 2015 with PD-1 and CTLA-4 axis blocking-based monoclonal antibodies (mAbs).